Medicare Rx "On Track And On Schedule," CMS' McClellan Says; "Non-Interference" Not An Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate's rejection of legislation to allow HHS intervention in Medicare drug price negotiations reflects the Centers for Medicare & Medicaid Services' confidence that the new outpatient drug benefit will be working as planned on Jan. 1, CMS Administrator Mark McClellan said March 17
You may also be interested in...
HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause
The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.
HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause
The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.
PhRMA Works For Medicare: Partnership With Unions Will Help Part D Roll-Out
The Pharmaceutical Research & Manufacturers of America will work through a formal partnership with organized labor to promote the Medicare Part D benefit to retirees